Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best stocks under $25 to buy now. Cantor Fitzgerald reaffirmed its Overweight rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on December 19, citing a strong outlook for the company. Summit’s upcoming global phase 3 HARMONi-3 study, which will evaluate ivonescimab plus chemotherapy in first-line non-small cell lung cancer (NSCLC), was noted as a critical milestone for 2026.

Summit Therapeutics Inc. (NASDAQ:SMMT) has stated that it would divide its HARMONi-3 trial into two histological cohorts, comparing ivonescimab with chemotherapy to pembrolizumab plus chemotherapy in the first-line regimen for metastatic squamous and non-squamous NSCLC.

The company intends to present preliminary findings for the HARMONi-3 squamous population in the latter half of 2026, with enrollment in the non-squamous cohort projected to conclude in the same period. Summit Therapeutics Inc. (NASDAQ:SMMT) estimates that the non-squamous cohort will pass the progression-free survival event threshold in the first half of 2027.

According to Cantor Fitzgerald, the study’s findings have the potential to be “biotech’s most important catalyst in 2026” and “the biggest binary event in the history of biotech.”

Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company developing treatments for serious unmet medical needs, primarily in oncology, with its lead drug, ivonescimab, a bispecific antibody.

While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.